BindingDB Data by Journal




PMID
Data
Article Title
Citation
Organization
Download Data
Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesisBDB
WIPO 0: 0-0 (2005)
Pfizer
MAP4K1 INHIBITORSBDB
WIPO 0: 0-0 (2023)
Blueprint Medicines
Compounds and method of treating covid-19BDB
WIPO 0: 0-0 (2021)
Pfizer
Compounds and methods for the treatment of covid-19BDB
WIPO 0: 0-0 (2021)
Pfizer
Nitrile-containing antiviral compoundsBDB
WIPO 0: 0-0 (2021)
Pfizer
Sars-cov-2 inhibitors having covalent modifications for treating coronavirus infectionsBDB
WIPO 0: 0-0 (2021)
Insilico Medicine Ip
ANTIVIRAL HETEROARYL KETONE DERIVATIVESBDB
WIPO 0: 0-0 (2022)
Pfizer
CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORSBDB
WIPO 0: 0-0 (2022)
Janssen Pharmaceutica
Aminocarbamoyl compounds for the treatment of viral infectionsBDB
WIPO 0: 0-0 (2022)
F. Hoffmann-La Roche
TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORSBDB
WIPO 0: 0-0 (2022)
Bristol-Myers Squibb
DIHYDROOROTATE DEHYDROGENASE INHIBITORSBDB
WIPO 0: 0-0 (2022)
Janssen Biotech
PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORSBDB
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
NOVEL CORONAVIRUS MAIN PROTEASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOFBDB
WIPO 0: 0-0 (2022)
Sichuan University
DIHYDROOROTATE DEHYDROGENASE INHIBITORSBDB
WIPO 0: 0-0 (2022)
Janssen Biotech
DIHYDROOROTATE DEHYDROGENASE INHIBITORSBDB
WIPO 0: 0-0 (2022)
Janssen Biotech
AMINOIMIDAZOLE FPR2 AGONISTSBDB
WIPO 0: 0-0 (2022)
Bristol-Myers Squibb
PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORSBDB
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSISBDB
WIPO 0: 0-0 (2022)
Novartis
SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCERBDB
WIPO 0: 0-0 (2022)
The Broad Institute
SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCERBDB
WIPO 0: 0-0 (2022)
The Broad Institute
PHOSPHOLIPID COMPOUNDS AND USES THEREOFBDB
WIPO 0: 0-0 (2022)
Gilead Sciences
7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1BDB
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOFBDB
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCERBDB
WIPO 0: 0-0 (2022)
Genentech
1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA|MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIABDB
WIPO 0: 0-0 (2022)
Genentech
SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASEBDB
WIPO 0: 0-0 (2022)
Janssen Pharmaceutica
CYCLOPENTATHIOPHENE CARBOXAMIDE DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTSBDB
WIPO 0: 0-0 (2022)
Boehringer Ingelheim International
INTERLEUKIN-17 INHIBITORSBDB
WIPO 0: 0-0 (2022)
Novartis
SUBSTITUTED MORPHOLINE COMPOUNDSBDB
WIPO 0: 0-0 (2022)
Genentech
HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USEBDB
WIPO 0: 0-0 (2022)
Amgen
ETHER-LINKED ANTIVIRAL COMPOUNDSBDB
WIPO 0: 0-0 (2022)
Pfizer
COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASESBDB
WIPO 0: 0-0 (2022)
Novartis
INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7)BDB
WIPO 0: 0-0 (2023)
Dana-Farber Cancer Institute
CORONAVIRUS MAIN PROTEASE INHIBITORS AND METHODS USING SAMEBDB
WIPO 0: 0-0 (2023)
Baylor College Of Medicine
CDK7 SELECTIVE INHIBITORS AS ANTICANCER AGENTSBDB
WIPO 0: 0-0 (2023)
Jingrui Biopharma
NOVEL FATTY ACID MODIFIED UROCORTIN 2 DERIVATIVES AND THE USES THEREOFBDB
WIPO 0: 0-0 (2023)
Novo Nordisk
TRICYCLIC COMPOUNDSBDB
WIPO 0: 0-0 (2023)
Recurium Ip Holdings
M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATESBDB
WIPO 0: 0-0 (2023)
Lycia Therapeutics
POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDSBDB
WIPO 0: 0-0 (2022)
Gilead Sciences
TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF RED BLOOD DISORDERS AND INFLAMMATORY DISEASESBDB
WIPO 0: 0-0 (2022)
Sanofi
AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITYBDB
WIPO 0: 0-0 (2022)
Shionogi &Amp
MACROCYCLIC UREA OREXIN RECEPTOR AGONISTSBDB
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATORBDB
WIPO 0: 0-0 (2022)
Vertex Pharmaceuticals
INHIBITION OF TYK2 DEPENDENT SIGNALING PATHWAYSBDB
WIPO 0: 0-0 (2022)
Janssen Pharmaceutica
ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTIONBDB
WIPO 0: 0-0 (2022)
F. Hoffmann-La Roche
MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORSBDB
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
AROMATIC BRIDGED RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTIONBDB
WIPO 0: 0-0 (2022)
F. Hoffmann-La Roche
AROMATIC SPIRO RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTIONBDB
WIPO 0: 0-0 (2022)
F. Hoffmann-La Roche
SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORSBDB
WIPO 0: 0-0 (2022)
Boehringer Ingelheim International
7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1BDB
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1BDB
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
PYRAZOLE DERIVATIVES ASR ET KINASE INHIBITORSBDB
WIPO 0: 0-0 (2022)
Eli Lilly
N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCERBDB
WIPO 0: 0-0 (2022)
Bayer Aktiengesellschaft
SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTIONBDB
WIPO 0: 0-0 (2022)
F. Hoffmann-La Roche
ISOINDOLINONE COMPOUNDSBDB
WIPO 0: 0-0 (2021)
Monte Rosa Therapeutics
SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONBDB
WIPO 0: 0-0 (2022)
Sanofi
N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTIONBDB
WIPO 0: 0-0 (2022)
F. Hoffmann-La Roche
(AZA)BENZOTHIAZOLYL SUBSTITUTED PYRAZOLE COMPOUNDSBDB
WIPO 0: 0-0 (2022)
Pfizer
3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTSBDB
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
SARS-COV-2 MPRO INHIBITOR COMPOUNDSBDB
WIPO 0: 0-0 (2022)
Heptares Therapeutics
SEROTONIN 5-HT2A, 5-HT2B, AND 5-HT2C RECEPTOR INVERSE AGONISTSBDB
WIPO 0: 0-0 (2023)
Northeastern University
INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETOBDB
WIPO 0: 0-0 (2023)
Mindset Pharma
Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesisBDB
WIPO 0: 0-0 (2006)
Pfizer